DISCLAIMER: This page is intended for members of the general public in Canada only.

The information provided on this site is intended for general information and education for Canada-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.

Information about the NuvaxovidTM COVID-19 Vaccine (Recombinant protein, Adjuvanted) (also known as NVX-CoV2373)

NuvaxovidTM COVID-19 Vaccine (Recombinant protein, Adjuvanted) is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older and as a homologous booster given approximately 6 months after completion of the second dose of the primary series in individuals 18 years of age and older.

Drug Identification Number (DIN): 02525364

Report an Adverse Event (AE)

If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Patient Medication Information.

Either you or your healthcare professional can report any suspected adverse reactions to Health Canada by:

Product Quality Complaint

If you would like to report a complaint regarding the quality of a product, you can access the Health Canada product complaint form via this link: www.healthycanadians.gc.ca/apps/radar/MD-IM-0005.08.html

Contact Us

Toll free: 1-855-239-9172 between 9 h 30 et 21 h 30 HT.
09:00 - 17:00
Monday - Friday